*** Need an answer to your GCP query ? Post your query at HelpDesk ***
Follow us on




Process validation

Establishing by objective evidence that a process consistently produces a result or product meeting its predetermined specifications.

 Forums
Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 12:12:20
Managing Clinical Trials   by  on 2010-07-15 16:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 10:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 10:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 09:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 09:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 11:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 11:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 01:40:32
 Subject :AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drug.. 2010-05-13 14:55:29 
GCP HelpDesk
Moderator
Joined: 2009-06-18 15:31:58
Posts: 62
Location
Subject :AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population

Dear Friends,
 
Please find attached American Academy of Pediatrics’ Clinical Report—Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations.
 
The proper ethical conduct of studies to evaluate drugs in children is of paramount importance to all those involved in these types of studies. This report is an updated revision to the previously published guidelines from the American Academy of Pediatrics in 1995. Since the previous publication, there have been great strides made in the science and ethics of studying drugs in children. There have also been numerous legislative and regulatory advancements that have promoted the study of drugs in children while simultaneously allowing for the protection of this particularly vulnerable group. This report summarizes these changes and advances and provides a framework from which to guide and monitor the ethical conduct of studies to evaluate drugs in children.
 
Kind regards,


IP Logged
Last Edited On: 2010-05-13 14:55:29 By GCP HelpDesk for the Reason
GCP HelpDesk
Page # 


Powered by ccBoard